CRNX CRINETICS PHARMACEUTICALS INC Product Launches 8-K Filing 2023 - Positive Phase 2 Study Findings Crinetics Pharmaceuticals announced positive initial findings from its ongoing Phase 2 study of paltusotine for the treatment of acromegaly and carcinoid syndrome, with reductions in symptoms and consistent safety profile.Get access to all SEC 8-K filings of the CRINETICS PHARMACEUTICALS INC